A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

@article{Parker2013ARD,
  title={A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.},
  author={Christopher C. Parker and Sarah Pascoe and Ale{\vs} Chodacki and J. M. O'Sullivan and Josep Ram{\'o}n Germ{\`a} and Charles Gillies O'Bryan-Tear and Trond Haider and Peter Hoskin},
  journal={European urology},
  year={2013},
  volume={63 2},
  pages={189-97}
}
BACKGROUND Patients with castration-resistant prostate cancer (CRPC) and bone metastases have an unmet clinical need for effective treatments that improve quality of life and survival with a favorable safety profile. OBJECTIVE To prospectively evaluate the efficacy and safety of three different doses of radium chloride (Ra 223) in patients with CRPC and bone metastases. DESIGN, SETTING, AND PARTICIPANTS In this phase 2 double-blind multicenter study, 122 patients were randomized to receive… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Alpha-emitting radium-223: two years follow-up from a randomized phase II study in patients with bone metastases from hormone-refractory prostate cancer [abstract P-7018

  • S Nilsson, L Franzen, C Parker
  • Eur J Cancer
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…